Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment

(2011) S. Chu et al.   BLOOD

Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease

(2011) J.-C. Chomel et al.   BLOOD

Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks: Figure 1.

(2011) Francesca Pellicano et al.   JOURNAL OF EXPERIMENTAL MEDICINE

BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

(2011) Christian Hurtz et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells

(2011) Faiyaz Notta et al.   NATURE

Exploiting the balance between life and death: Targeted cancer therapy and “oncogenic shock”

(2010) Sreenath V. Sharma et al.   BIOCHEMICAL PHARMACOLOGY

In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib

(2010) M. Sobrinho-Simoes et al.   BLOOD

BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells

(2010) M. Schemionek et al.   BLOOD

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Genetic variegation of clonal architecture and propagating cells in leukaemia

(2010) Kristina Anderson et al.   NATURE

Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia

(2009) Yaoyu Chen et al.   NATURE GENETICS

Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

(2009) A K Samanta et al.   ONCOGENE

Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis

(2008) Neil P. Shah et al.   CANCER CELL

Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells

(2008) H. Konig et al.   CANCER RESEARCH

Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells

(2008) Svetlana Myssina et al.   EXPERIMENTAL HEMATOLOGY

Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors

(2008) H Konig et al.   LEUKEMIA